Aug 25 2011 | News
WASHINGTON (AP) — The FDA has approved Allergan's Botox injection for a new use in patients who have bladder problems caused by spinal cord injury or multiple sclerosis.
|
Aug 8 2011 | News
Allergan has announce that BOTOX(R) (botulinum toxin type A)
has received a positive opinion from the Irish Medicines Board for the
management of urinary incontinence in adults with neurogenic detrusor
overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical
spinal cord injury, or multiple sclerosis.
|
Apr 29 2011 | News
A federal jury on Thursday awarded $212 million
to a Virginia
man who claimed injections of the wrinkle-smoothing drug Botox to treat hand
tremors and writer's cramp left him brain-damaged and disabled.
|
Apr 8 2011 | News
LOS ANGELES (AP) — Amgen Inc. Chairman and CEO Kevin W.
Sharer received compensation valued at about $21 million in 2010, a 38 percent
increase from what he got the year before, according to an Associated Press
review of the biotechnology company's proxy statement.
|
Feb 1 2011 | News
Allergan, Inc. and MAP Pharmaceuticals, Inc. have announced a collaboration
within the United States
for LEVADEX(TM), a self-administered, orally inhaled therapy that has completed
Phase III clinical development for the treatment of acute migraine in adults.
|
Sep 7 2010 | News
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%.
|
Jul 9 2010 | News
Allergan has announced that BOTOX(R) (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraine.
|
Jul 8 2010 | News
Rumours have emerged that French pharmaceutical giant Sanofi-Aventis is in the early stages of planning a reported $20 billion acquisition with the potential target thought to be US-based.
|
Mar 3 2010 | News
Bristol-Myers Squibb Company and Allergan, Inc. today announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain.
|
Feb 4 2010 | News
IRVINE, Calif. (AP) — Botox maker Allergan Inc. said Thursday its profit jumped 51 percent in the fourth quarter, but its forecasts for 2010 trended below Wall Street estimates.
|